Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Geltim LP 0.1% (unpreserved timolol gel) in glaucoma patients intolerant to Xalatan
2008-000580-41Phase 4Active
- Sponsor
- Laboratoires Théa
- Start
- Mar 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, single-arm trial of Geltim LP in Glaucoma and ocular hypertension, sponsored by Laboratoires Théa. Primary endpoints: Safety and ocular tolerance of Geltim LP 1 mg/g and Change in intraocular pressure. Started Mar 2008; status: active.
02
Drugs
Geltim LP
03
Conditions
Glaucomaocular hypertension
Beyond the preview
Go deeper on 2008-000580-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000580-41.